Why does chronic activation of the sympathetic nervous system and RAAS worsen outcomes in heart failure, even though the same reflexes are protective in acute blood loss?
Choose an answer, then check it.
Clinical Pharmacology · Heart Failure and Angina Medications
Heart Failure Therapies
On this page 6 sections
In 30 seconds
Modern heart failure with reduced ejection fraction (HFrEF) treatment is not about whipping a tired heart into working harder — it is about silencing the stress hormones that make things worse over time. Four drug classes, often called the "four pillars," each block a different piece of that hormonal cascade and are combined, not chosen one at a time, because together they cut hospitalizations and prolong life. Everything else — diuretics, hydralazine-nitrate combinations, ivabradine, digoxin, vericiguat, iron — treats symptoms or fills gaps for specific patients rather than forming the survival backbone. Heart failure with preserved ejection fraction (HFpEF) is a different disease physiologically, and its evidence base is much thinner.
The college version
Why the heart's own compensation backfires
When the heart's pumping ability drops, the body reads this as low blood flow and answers with two survival reflexes: the sympathetic nervous system fires harder, and the renin-angiotensin-aldosterone system (RAAS) retains sodium and water while constricting vessels. In a short-term crisis, like blood loss, that response is protective. In chronic heart failure, it is ruinous. Chronic sympathetic drive and angiotensin/aldosterone exposure remodel the heart muscle itself, promoting fibrosis, chamber enlargement, and worsening arrhythmia risk. This is why simply stimulating the heart with an inotrope, the older mental model of heart failure care, does not extend life. It runs a struggling engine harder without fixing why it is struggling, and can even hasten death. The therapeutic insight that reshaped modern practice is that surviving heart failure means interrupting the neurohormonal signal, not amplifying cardiac output.
The four pillars
An ARNI (sacubitril-valsartan) pairs a neprilysin inhibitor, which preserves protective natriuretic peptides, with an angiotensin receptor blocker, and is now generally preferred over a standalone ACE inhibitor or ARB when tolerated; an ACE inhibitor or ARB alone remains the fallback when an ARNI is not an option, since both interrupt RAAS-driven remodeling. An evidence-based beta blocker, meaning specifically carvedilol, metoprolol succinate, or bisoprolol rather than any beta blocker generically, blunts the chronic sympathetic surge on the heart. A mineralocorticoid receptor antagonist, either spironolactone or eplerenone, blocks aldosterone's fibrotic and sodium-retaining effects at the kidney and myocardium. An SGLT2 inhibitor, dapagliflozin or empagliflozin, was originally a diabetes drug but independently reduces heart failure hospitalization and mortality through mechanisms still being clarified, including favorable effects on cardiac loading, metabolism, and natriuresis. These four classes act on distinct pathways, so their benefits are additive rather than redundant, and guidelines now favor starting several simultaneously at low doses rather than fully optimizing one before adding the next.
Symptom-directed and adjunct therapy
Loop diuretics relieve congestion, edema, and dyspnea by promoting salt and water excretion, but they have never been shown to extend survival; they manage comfort, not disease trajectory, and are used at the lowest dose that controls symptoms. Hydralazine combined with isosorbide dinitrate provides an alternative vasodilating strategy shown to help specifically in self-identified Black patients with HFrEF already on pillar therapy, and is also used when RAAS blockade cannot be tolerated due to kidney impairment. Ivabradine slows the heart's own pacemaker current in patients who remain fast despite adequate beta blockade and are in normal sinus rhythm, reducing hospitalization risk. Digoxin, discussed elsewhere for its inotropic mechanism, still has a role here purely for symptom control and reducing hospitalizations, without a mortality benefit and with a narrow safety margin. Vericiguat, a soluble guanylate cyclase stimulator, is reserved for patients with recent decompensation despite guideline therapy, adding another vasodilating and antifibrotic signal. Intravenous iron is used when iron deficiency is confirmed, since correcting it improves symptoms and reduces hospitalizations even without frank anemia.
HFpEF is a different problem
In heart failure with preserved ejection fraction, the primary defect is impaired relaxation and filling of a stiff ventricle rather than weak contraction, so many of the pillar drugs that target contractile remodeling show little or no mortality benefit. The clearest evidence-based interventions in HFpEF are SGLT2 inhibitors, which help across the ejection fraction spectrum, and diuretics for congestion. Clinicians should not assume the HFrEF playbook simply transfers.
Practical management realities
Every pillar drug is started at a low dose and titrated upward gradually as tolerated, because early hypotension, dizziness, or renal changes are common and typically resolve with time. ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists all raise potassium and can affect kidney function, so clinicians monitor serum potassium and creatinine at baseline and after dose changes, and the combination of an MRA with a RAAS inhibitor raises hyperkalemia risk further. Patients are taught to weigh themselves at the same time daily and report a rapid, unexplained gain, since fluid retention often shows up on the scale before it is felt as breathlessness or swelling. General guidance includes moderating dietary sodium and, in some patients, limiting fluid intake, individualized to severity. Certain drug classes are avoided or used cautiously in heart failure: NSAIDs blunt the effect of diuretics and RAAS inhibitors while promoting sodium retention, non-dihydropyridine calcium channel blockers such as verapamil and diltiazem have negative inotropic effects that can worsen HFrEF, and thiazolidinediones cause fluid retention that can precipitate decompensation. Recognizing these interactions is often what separates a stable outpatient from one cycling through hospital admissions.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of the heart as a tired employee and the body as a stressed-out boss. When the heart starts falling behind, the boss doesn't help it work smarter — it just yells louder and demands overtime. That yelling is the stress hormones flooding the body. For a while the heart pushes through, but working scared and exhausted for months wrecks it even more. The smart fix isn't a louder boss or an energy drink for the heart (that's what old-style stimulant drugs tried). The smart fix is telling the boss to calm down. Four different medicines each mute a different part of that yelling, and using all four together works far better than any one alone. Water pills are a separate tool entirely — they just drain the extra puddle of fluid that piles up so the person can breathe easier, but they don't fix the underlying yelling problem. And some everyday medicines, like common pain relievers, accidentally turn the yelling back up, which is why people with heart failure are told to avoid them.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with HFrEF started on a new medication for joint pain notices increasing ankle swelling and shortness of breath over the following week. What class of drug should be suspected, and why?
Show answer
NSAIDs should be suspected.
NSAIDs cause the body to retain sodium and fluid and can blunt how well diuretics and RAAS-blocking drugs work, so starting one can quietly push a stable heart failure patient back into fluid overload.
A patient on both an ARNI and spironolactone asks why the nurse keeps checking blood work after each dose increase. What should the nurse monitor for, and why is this combination particularly important to watch?
Show answer
The nurse should monitor serum potassium and kidney function (creatinine).
Both an ARNI and a mineralocorticoid receptor antagonist can raise potassium and affect renal function on their own, so combining them meaningfully increases the risk of dangerous hyperkalemia, making lab checks after each dose change especially important.
Quick check
3 questions here. Answers stay hidden until you check.
Which of the following is NOT one of the four foundational pillars of guideline-directed medical therapy for HFrEF?
Choose an answer, then check it.
Which statement best describes the evidence base in heart failure with preserved ejection fraction (HFpEF) compared with HFrEF?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.